GLP-1 receptor agonists, originally developed to help control blood sugar in patients with diabetes in Novo's Nordisk's Ozempic and Mounjaro developed by Eli Lilly, also slow digestion and reduce hunger.AMSTERDAM – The European Union drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo Nordisk 's hugely popular Wegovy, are linked to suicidal thoughts , it said on Friday, ending a nine-month probe.
The finding comes after EMA extended in December its review into the class of weight-loss and diabetes drugs, known as GLP-1 receptor agonists, to get more data from drugmakers to further investigate the issue. The EMA analysed results from a large US study and did not find a direct association between the use of semaglutide and suicidal thoughts.
"I hope it's reassuring to patients and prescribers that after a thorough review by two regulatory agencies ... there does not appear to be an increased risk of suicidal behaviour," said Dr Robert Kushner, professor at Northwestern University Feinberg School of Medicine. Dr Alison Cave, the agency's chief safety officer, said that the review continued and the agency would "communicate any further advice to patients and healthcare professionals as appropriate."
But doctors are on the lookout for previously undocumented dangers as hundreds of thousands of new patients start taking these drugs to lose weight.
Suicidal Thoughts European Medicines Agency Novo Nordisk Diabetes Drugs Semaglutide Liraglutide GLP-1 Targeting Compounds
پاکستان تازہ ترین خبریں, پاکستان عنوانات
Similar News:آپ اس سے ملتی جلتی خبریں بھی پڑھ سکتے ہیں جو ہم نے دوسرے خبروں کے ذرائع سے جمع کی ہیں۔
ذریعہ: DunyaNews - 🏆 1. / 83 مزید پڑھ »
ذریعہ: BOLNETWORK - 🏆 9. / 63 مزید پڑھ »
ذریعہ: DunyaNews - 🏆 1. / 83 مزید پڑھ »
ذریعہ: BOLNETWORK - 🏆 9. / 63 مزید پڑھ »
ذریعہ: BOLNETWORK - 🏆 9. / 63 مزید پڑھ »
ذریعہ: BOLNETWORK - 🏆 9. / 63 مزید پڑھ »